ClinicalTrials.gg
CompletedNCT04403165LEADUpdated Nov 6, 2026Results posted

Locus-coeruleus Function in Normal Elderly and AD Risk

An interventional study of Nocturnal polysomnography (NPSG) and Lumbar Puncture (LP) in Alzheimer Disease, sponsored by NYU Langone Health. Completed at 2 sites in United States. Open to participants aged 55 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Basic science

How we know

Updated Nov 6, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
55 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Alzheimer Disease by NYU Langone Health — 2 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · NYU Langone Health.

Enrollment
8th of 15
34 · median 34
Started
2020
the only one that year
No phase
8 of 22
none open now
Registered
17th of 22
by date

Among the 22 studies in Alzheimer Disease by NYU Langone Health, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2020, is one of 8 with no phase, and was the 17th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 22 studies in Alzheimer Disease by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Alzheimer Disease by NYU Langone Health, or all of them as a file.
02

Study summary

Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed since midlife. We have previously demonstrated functional vulnerability of the LC to aging and stress, as well as an association between higher cerebrospinal fluid (CSF) tau and impaired sleep phenomena influenced by the LC. We now aim to test whether LC dysfunction can be measured in preclinical AD stages by LC targeted imaging, and whether it objectively affects sleep architecture and attention. We will test this hypothesis in 30 cognitively normal older adults by performing a full clinical evaluation, one night of polysomnography, a lumbar puncture to obtain cerebrospinal fluid, [11C]MRB PET-MR, and attention testing. This study has the potential to identify a new mechanism by which tau pathology contributes to sleep and attention dysfunction and may provide a new therapeutic target for AD prevention.

Read the detailed description

The purpose of this study is three-fold: to test whether lower NET availability in the LC is associated with: first, CSF tau levels typical of preclinical stages of AD (Aim 1); second, reduced REM and spindle density (Aim 2); and third, impaired performance on attention tasks (Aim 3). The goal is to test the overarching hypothesis that LC dysfunction occurs in preclinical AD stages, can be measured with MRB-PET, and translates into impairment of sleep architecture (LC tonic dysfunction) and attention (LC phasic dysfunction).

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects with normal cognition and 55-75 years of age will be enrolled.
  • Subjects will be within normal limits on neurological and psychiatric examinations.
  • All subjects enrolled will have a CDR of 0. This will be evaluated through a clinical interview administered by a study physician (informant interview will not be required).
  • All subjects will have had a minimum of 12 years of education.

Exclusion criteria

Exclusion Criteria:

  • History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, stroke, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders).
  • Significant history of alcoholism or drug abuse.
  • Significant history of psychiatric illness (e.g., schizophrenia, bipolar, PTSD, or life-long history of major depression).
  • Geriatric Depression Scale (short form)>6.
  • Insulin dependent diabetes.
  • Evidence of cardiac, pulmonary, endocrine or hematological conditions.
  • Physical impairment of such severity as to adversely affect the validity of psychological testing.
  • Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.
  • History of a first-degree family member with early onset (age \<60 years) dementia.
  • Irregular sleep-wake rhythms (based on the actigraphy recordings) or significant OSA (AHI4%≥15).
  • Taking Coumadin/warfarin and/or medications affecting cognition or sleep.
  • Failure to complete all study visit within 4 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Cognitively Normal (CN) Older Adults

    Procedure: Nocturnal polysomnography (NPSG) · Procedure: Lumbar Puncture (LP) · Other: PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB) · Behavioral: Psychomotor Vigilance Task (PVT)

Interventions

  • ProcedureNocturnal polysomnography (NPSG)

    Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics.

  • ProcedureLumbar Puncture (LP)

    Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio.

  • OtherPET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB)

    PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-\[11C\]O-methylreboxetine (\[11C\]MRB) to measure NET availability.

  • BehavioralPsychomotor Vigilance Task (PVT)

    Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance.

06

What researchers measure

Primary outcomes

  1. Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values

    Time frame: Visit 4 (1-4 weeks after LP that occurred on day 14)

  2. Total Rapid Eye Movement (REM) Duration (Min)

    REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

    Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

  3. Percentage of Time Spent in REM Sleep

    REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

    Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

  4. Percentage of REM Runs That Are Less Than 5 Minutes

    Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

  5. Percentage of REM Runs That Are Greater Than or Equal to 5 Minutes

    Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

  6. Percentage of REM Runs That Are Greater Than or Equal to 10 Minutes

    Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

  7. Percentage of Correct Responses on the Picture Test

    The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System.

    Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

  8. Number of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density)

    N2 Spindle Density is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

    Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

  9. Mean Psychomotor Vigilance Test (PVT) Reaction Time

    PVT measures the reaction speed to a randomly time-occuring visual stimuli, allowing the assessment of several aspects of attention including response times, attention lapses and false starts.

    Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

  10. Picture Test Response Time

    The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System.

    Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

Secondary outcomes

  1. Levels of Hyperphosphorylated Tau (P-Tau)

    Levels will be derived from the plasma and reported in pg/mL

    Time frame: Visit 4 (1-4 weeks after LP that occurred on day 14)

07

Results

Posted Nov 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneCognitively Normal (CN) Older Adults
Started34
Completed26
Not completed8
Withdrew: Lost to follow-up6
Withdrew: Withdrawal by subject1
Withdrew: Met pre-specified exclusion criteria1

Outcome measures

PrimaryMethylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values
Time frame:
Visit 4 (1-4 weeks after LP that occurred on day 14)
Reported as:
Mean · Mean Standardized Uptake Value Ratio
Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values
Mean Standardized Uptake Value RatioCognitively Normal (CN) Older Adults
Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values0.95 ± 0.52
PrimaryTotal Rapid Eye Movement (REM) Duration (Min)

REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

Time frame:
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Reported as:
Mean · Minutes
Total Rapid Eye Movement (REM) Duration (Min)
MinutesCognitively Normal (CN) Older Adults
Total Rapid Eye Movement (REM) Duration (Min)74.75 ± 38.7
PrimaryPercentage of Time Spent in REM Sleep

REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

Time frame:
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Reported as:
Median · Percentage of total sleep time
Percentage of Time Spent in REM Sleep
Percentage of total sleep timeCognitively Normal (CN) Older Adults
Percentage of Time Spent in REM Sleep21.1 (15.53 to 26.65)
PrimaryPercentage of REM Runs That Are Less Than 5 Minutes
Time frame:
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Reported as:
Median · Percentage of REM runs
Percentage of REM Runs That Are Less Than 5 Minutes
Percentage of REM runsCognitively Normal (CN) Older Adults
Percentage of REM Runs That Are Less Than 5 Minutes20 ± 35
PrimaryPercentage of REM Runs That Are Greater Than or Equal to 5 Minutes
Time frame:
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Reported as:
Median · Percentage of REM runs
Percentage of REM Runs That Are Greater Than or Equal to 5 Minutes
Percentage of REM runsCognitively Normal (CN) Older Adults
Percentage of REM Runs That Are Greater Than or Equal to 5 Minutes80 ± 35
PrimaryPercentage of REM Runs That Are Greater Than or Equal to 10 Minutes
Time frame:
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Reported as:
Median · Percentage of REM runs
Percentage of REM Runs That Are Greater Than or Equal to 10 Minutes
Percentage of REM runsCognitively Normal (CN) Older Adults
Percentage of REM Runs That Are Greater Than or Equal to 10 Minutes56.35 ± 43.89
PrimaryPercentage of Correct Responses on the Picture Test

The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System.

Time frame:
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Reported as:
Median · Percentage of correct responses
Percentage of Correct Responses on the Picture Test
Percentage of correct responsesCognitively Normal (CN) Older Adults
Percentage of Correct Responses on the Picture Test90.62 ± 9.38
PrimaryNumber of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density)

N2 Spindle Density is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

Time frame:
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Reported as:
Median · spindles/min
Number of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density)
spindles/minCognitively Normal (CN) Older Adults
Number of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density)0.23 ± 0.53
PrimaryMean Psychomotor Vigilance Test (PVT) Reaction Time

PVT measures the reaction speed to a randomly time-occuring visual stimuli, allowing the assessment of several aspects of attention including response times, attention lapses and false starts.

Time frame:
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Reported as:
Median · milliseconds
Mean Psychomotor Vigilance Test (PVT) Reaction Time
millisecondsCognitively Normal (CN) Older Adults
Mean Psychomotor Vigilance Test (PVT) Reaction Time277.9 ± 42.27
PrimaryPicture Test Response Time

The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System.

Time frame:
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Reported as:
Median · Seconds
Picture Test Response Time
SecondsCognitively Normal (CN) Older Adults
Picture Test Response Time1.2 ± 1.05
SecondaryLevels of Hyperphosphorylated Tau (P-Tau)

Levels will be derived from the plasma and reported in pg/mL

Time frame:
Visit 4 (1-4 weeks after LP that occurred on day 14)
Reported as:
Mean · pg/mL
Levels of Hyperphosphorylated Tau (P-Tau)
pg/mLCognitively Normal (CN) Older Adults
Levels of Hyperphosphorylated Tau (P-Tau)0.34 ± 0.15

Adverse events

Collected over Adverse events, serious adverse events, and all-cause mortality were assessed only during the course of each participant's active study procedures (home sleep monitoring, in-lab NPSG, PET/MR imaging, and blood collection), with no post-study follow-up period (up to 8 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cognitively Normal (CN) Older Adults0/34 (0%)0/34 (0%)0/34 (0%)

Baseline characteristics

All participants for which demographic information was collected were included in the demographics analysis.

Age, Continuous
Age, Continuous(years)Cognitively Normal (CN) Older Adults
Mean62.65 ± 5.1
Sex: Female, Male
Sex: Female, Male(Participants)Cognitively Normal (CN) Older Adults
Female21
Male11
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cognitively Normal (CN) Older Adults
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American14
White17
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cognitively Normal (CN) Older Adults
Hispanic or Latino2
Not Hispanic or Latino23
Unknown or Not Reported7
Region of Enrollment
Region of Enrollment(participants)Cognitively Normal (CN) Older Adults
United States32
08

Study locations

2 sites
  • NYU Grossman School of Medicine
    New York, New York 10016, United States
  • Icahn School of Medicine Mount Sinai
    New York, New York 10029, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Immediately following publication. No end date.

Access criteria: The investigator who proposed to use the ricardo.osorio@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Mar 2024, 43 months.

Results were first posted in Nov 2026, 2 years 7 months after primary completion. A results delay was requested in Mar 2025.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 43 months is above that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2020
First posted
May 27, 2020
StartActual
Aug 6, 2020
Primary completionActual
Mar 26, 2024
CompletionActual
Mar 26, 2024
Results delay requested
Mar 10, 2025
Results first posted
Nov 6, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 6, 2026
Enrollment
30→34
Nov 6, 2026
Primary outcomes
3 edited, 4 time frame changed, 3 added, 1 removed
What changed in the outcomes
  • EditedNumber of sleep spindles that occur per minute duringSleep Spindles That Occur Per Minute During the N2 stageStage of sleepSleep (N2 Spindle Density)Time frame: Visit 3 (1-4 weeks after Visit 2) → Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
  • EditedMean picture test response timePicture Test Response TimeTime frame: Visit 3 (1-4 weeks after Visit 2) → Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
  • EditedPercentage of Correct Responses on the picture testPicture TestTime frame: Visit 3 (1-4 weeks after Visit 2) → Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
  • AddedPercentage of REM Runs That Are Less Than 5 MinutesTime frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
  • AddedPercentage of REM Runs That Are Greater Than or Equal to 5 MinutesTime frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
  • AddedPercentage of REM Runs That Are Greater Than or Equal to 10 MinutesTime frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
  • RemovedREM Sleep ContinuityTime frame: Visit 3 (1-4 weeks after Visit 2)
  • Time frameMethylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) ValuesVisit 4 (1-4 weeks after LP) → Visit 4 (1-4 weeks after LP that occurred on day 14)
  • Time frameTotal Rapid Eye Movement (REM) Duration (Min)Visit 3 (1-4 weeks after Visit 2) → Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
  • Time framePercentage of Time Spent in REM SleepVisit 3 (1-4 weeks after Visit 2) → Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
  • Time frameMean Psychomotor Vigilance Test (PVT) Reaction TimeVisit 3 (1-4 weeks after Visit 2) → Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Nov 6, 2026
Secondary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedLevels of Hyperphosphorylated Tau (P-Tau, T-Tau)Time frame: Visit 4 (1-4 weeks after LP) → Visit 4 (1-4 weeks after LP that occurred on day 14)
  • Removedother outcomeAβ42/Aβ40 RatioTime frame: Visit 4 (1-4 weeks after LP)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Results posted
    Enrollment 30→34
    Primary outcomes 3 edited, 4 time frame changed, 3 added, 1 removed
    What changed in the outcomes
    • EditedNumber of sleep spindles that occur per minute duringSleep Spindles That Occur Per Minute During the N2 stageStage of sleepSleep (N2 Spindle Density)Time frame: Visit 3 (1-4 weeks after Visit 2) → Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
    • EditedMean picture test response timePicture Test Response TimeTime frame: Visit 3 (1-4 weeks after Visit 2) → Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
    • EditedPercentage of Correct Responses on the picture testPicture TestTime frame: Visit 3 (1-4 weeks after Visit 2) → Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
    • AddedPercentage of REM Runs That Are Less Than 5 MinutesTime frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
    • AddedPercentage of REM Runs That Are Greater Than or Equal to 5 MinutesTime frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
    • AddedPercentage of REM Runs That Are Greater Than or Equal to 10 MinutesTime frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
    • RemovedREM Sleep ContinuityTime frame: Visit 3 (1-4 weeks after Visit 2)
    • Time frameMethylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) ValuesVisit 4 (1-4 weeks after LP) → Visit 4 (1-4 weeks after LP that occurred on day 14)
    • Time frameTotal Rapid Eye Movement (REM) Duration (Min)Visit 3 (1-4 weeks after Visit 2) → Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
    • Time framePercentage of Time Spent in REM SleepVisit 3 (1-4 weeks after Visit 2) → Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
    • Time frameMean Psychomotor Vigilance Test (PVT) Reaction TimeVisit 3 (1-4 weeks after Visit 2) → Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
    Secondary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedLevels of Hyperphosphorylated Tau (P-Tau, T-Tau)Time frame: Visit 4 (1-4 weeks after LP) → Visit 4 (1-4 weeks after LP that occurred on day 14)
    • Removedother outcomeAβ42/Aβ40 RatioTime frame: Visit 4 (1-4 weeks after LP)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04403165
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
May 27, 2020
Start date
Aug 6, 2020
Primary completion
Mar 26, 2024
Completion
Mar 26, 2024
Results posted
Nov 6, 2026
Last update
Nov 6, 2026

Study contacts

Ricardo Osorio
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion